This CPB has been revised to state that (i) Obizur (anti-hemophilic factor (recombinant), porcine sequence) is considered medically necessary for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVIII] deficiency), and (ii) Obizur is considered experimental and investigational for the treatment of congenital hemophilia A or von Willebrand disease.